CARD 12 Inhibitors
Caspase Recruitment Domain Family Member 12 (CARD12), also known as nucleotide-binding oligomerization domain-containing protein 9 (NOD9), is a protein involved in innate immune responses and inflammatory signaling pathways. It is a member of the nucleotide-binding oligomerization domain (NOD)-like receptor (NLR) family, which plays a crucial role in detecting microbial pathogens and initiating immune responses. CARD12 contains several functional domains, including a caspase recruitment domain (CARD) at its N-terminus, a nucleotide-binding domain (NBD), and leucine-rich repeat (LRR) motifs. These domains enable CARD12 to interact with other proteins involved in signaling cascades, particularly those related to the activation of nuclear factor-kappa B (NF-κB) and mitogen-activated protein kinases (MAPKs).
Inhibition of CARD12 typically occurs through various mechanisms that interfere with its normal function in inflammatory signaling pathways. One common mechanism involves the blockade of protein-protein interactions mediated by the CARD domain of CARD12. This can be achieved through the use of small molecule inhibitors or peptides that target the CARD domain and disrupt its interactions with downstream signaling molecules, thereby blocking the activation of NF-κB and other inflammatory pathways. Additionally, inhibition of CARD12 activity can also be achieved through the modulation of upstream regulators or downstream effectors involved in its signaling cascades. For instance, inhibition of key kinases or phosphatases involved in the activation of NF-κB or MAPK pathways can indirectly suppress the activity of CARD12. Moreover, strategies targeting the expression or stability of CARD12 mRNA or protein can also effectively inhibit its function in inflammatory responses. Overall, inhibition of CARD12 provides an approach for modulating inflammatory signaling and mitigating excessive immune responses associated with various inflammatory diseases.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Syk Inhibitor IV, BAY 61-3606 HCl | 732983-37-8 | sc-202351 | 2 mg | $327.00 | 25 | |
BAY 61-3606 is a selective inhibitor of Syk, a kinase involved in CARD12 signaling pathways. By inhibiting Syk, BAY 61-3606 disrupts the transduction of signals from upstream receptors to CARD12, directly interfering with the protein's activation. This compound showcases the potential for kinase-specific inhibition as a strategy to modulate CARD12 function and provides insights into the regulatory mechanisms governing the protein's involvement in cellular signaling cascades. | ||||||
PF-06465469 | 1407966-77-1 | sc-480369 | 5 mg | $83.00 | ||
PF-06465469, a selective and potent inhibitor of RIP2 kinase, directly influences CARD12-mediated signaling pathways. By inhibiting RIP2, PF-06465469 disrupts the downstream events that lead to CARD12 activation, providing a targeted approach to inhibit the protein's functionality. This compound highlights the intricate interplay between kinases in CARD12 signaling and offers a specific strategy for modulating CARD12 activity in cellular processes. | ||||||
Tirabrutinib | 1351636-18-4 | sc-507435 | 10 mg | $138.00 | ||
ONO-4059 is a BTK (Bruton's tyrosine kinase) inhibitor that indirectly impacts CARD12 by disrupting BTK-mediated signaling. Since BTK is involved in CARD12 activation, inhibition by ONO-4059 leads to downstream effects that modulate CARD12 function. This compound exemplifies the potential for targeting upstream regulators to indirectly influence CARD12, providing insights into the regulatory network governing the protein's involvement in cellular signaling pathways. | ||||||
Bemcentinib | 1037624-75-1 | sc-507363 | 10 mg | $900.00 | ||
R428, also known as BGB324, is a selective inhibitor of AXL, a receptor tyrosine kinase linked to CARD12 signaling pathways. By inhibiting AXL, R428 disrupts the transduction of signals from upstream receptors to CARD12, directly interfering with the protein's activation. | ||||||
IKK-2 Inhibitor IV | 507475-17-4 | sc-203083 | 500 µg | $133.00 | 12 | |
IKK-2 Inhibitor IV (TPCA-1) is a selective inhibitor of IKK-2, a kinase involved in NF-κB signaling downstream of CARD12. By inhibiting IKK-2, TPCA-1 disrupts the transduction of signals from CARD12 to NF-κB, directly interfering with the protein's downstream effects. | ||||||
AZD8330 | 869357-68-6 | sc-364425 sc-364425A | 5 mg 10 mg | $255.00 $450.00 | ||
AZD8330 is a selective MEK inhibitor that indirectly impacts CARD12 by disrupting the MEK-ERK signaling pathway, which is linked to CARD12 activation. Inhibition of MEK by AZD8330 leads to downstream effects that modulate CARD12 function, highlighting the potential for targeting upstream regulators to indirectly influence CARD12. | ||||||
BX 795 | 702675-74-9 | sc-281689 sc-281689A sc-281689C sc-281689B sc-281689D sc-281689E | 2 mg 5 mg 10 mg 25 mg 50 mg 100 mg | $219.00 $273.00 $331.00 $495.00 $882.00 $1489.00 | 5 | |
BX-795 is a PDK1 inhibitor that indirectly influences CARD12 by disrupting the PDK1-AKT signaling pathway, which is linked to CARD12 activation. Inhibition of PDK1 by BX-795 leads to downstream effects that modulate CARD12 function, exemplifying the potential for targeting upstream regulators to indirectly influence CARD12. | ||||||